Celularity Inc
Datakwaliteit: 100%
€ 1,27
▼
€ 0,09
(-6,62%)
Marktkapitalisatie: 38,93 M
Prijs
€ 1,35
Marktkapitalisatie
38,93 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Negative free cash flow of -6,68 M
Capital efficient — spends only 0,31% of revenue on capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)138,11%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC-76,69%
Net Margin-198,75%
Op. Margin-119,60%
Veiligheid
Debt / Equity
N/A
Current Ratio0,16
Interest CoverageN/A
Waardering
PE (TTM)
-0,48
Boven sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1385 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1385 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,5 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -54,4 |
| Net Margin % | -198,8 | -41,5 |
| Rev Growth 5Y % | — | 1,9 |
| D/E | — | 0,3 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
Geen toekomstige schattingen beschikbaar
No quarterly estimates available
Winstverassingen
Laatste 2 kwartalen
| Kwartaal | Geschat WPA | Werkelijk WPA | Verrassing |
|---|---|---|---|
| Q22023 | -€ 0,30 | -€ 2,70 | -800,0% |
| Q12023 | -€ 2,40 | -€ 4,10 | -70,8% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 138,11% | Revenue Growth (3Y) | 73,68% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 40,58 M | Net Income (TTM) | -80,65 M |
| ROE | N/A | ROA | -68,78% |
| Gross Margin | N/A | Operating Margin | -119,60% |
| Net Margin | -198,75% | Free Cash Flow (TTM) | -6,68 M |
| ROIC | -76,69% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,16 |
| Interest Coverage | N/A | Asset Turnover | 0,35 |
| Working Capital | -54,72 M | Tangible Book Value | -35,57 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,48 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 0,96 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -17,17% | ||
| Market Cap | 38,93 M | Enterprise Value | 38,81 M |
| Per Share | |||
| EPS (Diluted TTM) | -3,33 | Revenue / Share | 1,41 |
| FCF / Share | -0,23 | OCF / Share | -0,23 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,31% | FCF Conversion | 8,29% |
| SBC-Adj. FCF | -7,47 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 54,22 M | 22,77 M | 17,98 M | 21,34 M | — |
| Net Income | -57,89 M | -196,30 M | 14,19 M | -100,12 M | -2,63 M |
| EPS (Diluted) | -2,64 | -11,02 | 0,09 | — | — |
| Gross Profit | — | 6,76 M | -1,69 M | 11,68 M | — |
| Operating Income | -38,36 M | -192,29 M | -25,60 M | -109,06 M | -4,22 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 17,39 M | 30,47 M | 78,36 M | 88,35 M | — |
| SG&A Expenses | 58,64 M | 50,58 M | 66,02 M | 71,34 M | — |
| D&A | 7,92 M | 9,32 M | 9,44 M | 8,82 M | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 10.000,0 | 10.000,0 | 13.000,0 | 20.000,0 | 191.644,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 132,68 M | 143,89 M | 401,07 M | 414,13 M | 292,16 M |
| Total Liabilities | 123,85 M | 102,93 M | 202,17 M | 314,71 M | 14,22 M |
| Shareholders' Equity | 8,84 M | 40,96 M | 198,90 M | 99,42 M | 5,00 M |
| Total Debt | — | 17,22 M | 37,60 M | — | — |
| Cash & Equivalents | 738.000,0 | 227.000,0 | 13,97 M | 37,24 M | 314.696,0 |
| Current Assets | 20,56 M | 19,79 M | 33,50 M | 59,10 M | 359.289,0 |
| Current Liabilities | 53,68 M | 67,30 M | 62,09 M | 26,23 M | 3,41 M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#71 of 245
Recente Activiteit
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Apr 12, 2026
{"event":"ticker_viewed","properties":{"ticker":"CELU","listing_kind":"stock","pathname":"/stocks/celu","exchange":"NASDAQ","country":"US"}}